MZL
MCID: MRG003
MIFTS: 52

Marginal Zone B-Cell Lymphoma (MZL)

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Marginal Zone B-Cell Lymphoma

MalaCards integrated aliases for Marginal Zone B-Cell Lymphoma:

Name: Marginal Zone B-Cell Lymphoma 12 15 37 17 71
Marginal Zone Lymphoma 12 20 58
Mucosa-Associated Lymphoid Tissue Lymphoma 71
Mzl 20

Characteristics:

Orphanet epidemiological data:

58
marginal zone lymphoma
Prevalence: 1-9/100000 (France),1-9/100000 (Europe); Age of onset: Adult; Age of death: adult,elderly;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:0050748
UMLS via Orphanet 72 C0242647
Orphanet 58 ORPHA300912
UMLS 71 C0242647 C1367654

Summaries for Marginal Zone B-Cell Lymphoma

Disease Ontology : 12 A B-cell lymphoma that is characterized by initial formation in the marginal zones of lymph tissue.

MalaCards based summary : Marginal Zone B-Cell Lymphoma, also known as marginal zone lymphoma, is related to primary cutaneous marginal zone b-cell lymphoma and nodal marginal zone b-cell lymphoma. An important gene associated with Marginal Zone B-Cell Lymphoma is BCL6 (BCL6 Transcription Repressor), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Fludarabine and Chlorambucil have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, breast and thyroid, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Marginal Zone B-Cell Lymphoma

Diseases related to Marginal Zone B-Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 496)
# Related Disease Score Top Affiliating Genes
1 primary cutaneous marginal zone b-cell lymphoma 33.3 MALT1 IRF4 BCL10
2 nodal marginal zone b-cell lymphoma 33.1 MALT1 BCL6
3 splenic marginal zone lymphoma 32.9 MALT1 CD5 BIRC3 BCL6
4 nodal marginal zone lymphoma 32.4 SPN MME KDM4C IRF4 IGHV4-38-2 CD5
5 b-cell lymphoma 31.8 MYD88 MME MIR142 MALT1 IRF4 CD5
6 lymphoma 31.7 MYD88 MALT1 IRF4 CD5 CD19 CCR6
7 lymphoma, mucosa-associated lymphoid type 31.6 TNFAIP3 SPN SIGLEC5 MYD88 MME MIR142
8 follicular lymphoma 31.5 MME IRF4 CD5 BCL6 BCL10
9 gastric lymphoma 31.5 IRF4 BCL6 BCL10
10 plasmacytoma 31.4 IRF4 CD79A CD5
11 composite lymphoma 31.1 MME IGHV4-38-2 CD79A CD5 BCL6
12 peripheral t-cell lymphoma 31.0 MME CD5 CD19 BCL6
13 mantle cell lymphoma 30.9 SPN MME MALT1 CD5 CD40LG CD19
14 primary cutaneous diffuse large b-cell lymphoma, leg type 30.9 MYD88 IRF4
15 orbit lymphoma 30.9 MALT1 BIRC3 BCL10
16 lung lymphoma 30.9 SPN MME MALT1 CD79A CD5 BCL6
17 sjogren syndrome 30.8 TNFAIP3 CD79A CD40LG
18 cryoglobulinemia, familial mixed 30.8 CD5 CD40LG
19 gamma heavy chain disease 30.8 MYD88 IGHV4-38-2
20 cryoglobulinemia 30.7 CD79A CD5 CD40LG
21 heavy chain disease 30.7 MYD88 IGHV4-38-2 CD79A
22 central nervous system lymphoma 30.7 MYD88 MALT1 CCR6 BCL6
23 syphilis 30.7 CD79A CD40LG CCR6
24 secondary syphilis 30.7 CD79A CD40LG
25 monoclonal paraproteinemia 30.7 IGHV4-38-2 CD79A CD19
26 anemia, autoimmune hemolytic 30.6 IGHV4-38-2 CD5 CD40LG CD19 CCR6 C1S
27 t-cell/histiocyte rich large b cell lymphoma 30.6 MME BCL6
28 mulchandani-bhoj-conlin syndrome 30.6 MME CD40LG CD19 CCR6
29 intestinal disease 30.5 MIR142 KDM4C CCR6 BCL6
30 toxoplasmosis 30.5 MYD88 CD79A CD40LG
31 bladder lymphoma 30.5 SPN MME CD79A CD5 BCL6
32 cll/sll 30.5 SPN MME IGHV4-38-2 CD79A CD5 CD19
33 agammaglobulinemia 30.4 CD79A CD40LG CD19
34 t-cell adult acute lymphocytic leukemia 30.4 IRF4 CD5 CCR6 CARD11
35 breast lymphoma 30.4 SPN MME IRF4 CD79A CD5 BCL6
36 mature t-cell and nk-cell lymphoma 30.4 MME KDM4C CD79A CD5 CCR6 BCL6
37 burkitt lymphoma 30.4 MME IRF4 CD40LG CD19 BIRC3 BCL6
38 t-cell lymphoblastic leukemia/lymphoma 30.4 TNFAIP3 IRF4 CCR6 BIRC3
39 diffuse large b-cell lymphoma 30.4 TNFAIP3 SPN MYD88 MME MIR142 MALT1
40 connective tissue disease 30.3 SIGLEC5 MIR142 KDM4C CD40LG CCR6
41 gastrointestinal lymphoma 30.3 SPN MME MALT1 CD79A CD5 BIRC3
42 lymphoplasmacytic lymphoma 30.3 MYD88 MME KDM4C IGHV4-38-2 CD79A CD5
43 waldenstroem's macroglobulinemia 30.3 MYD88 IRF4 IGHV4-38-2 CD5 CD40LG CD19
44 richter's syndrome 30.2 SPN IRF4 IGHV4-38-2 CD5 CD19
45 celiac disease 1 30.2 TNFAIP3 MYD88 CD79A CD19 CCR6
46 b-lymphoblastic leukemia/lymphoma 30.1 MME CD19 CCR6
47 immune deficiency disease 30.0 SPN SIGLEC5 MIR142 CD79A CD5 CD40LG
48 myeloma, multiple 30.0 MYD88 MIR142 KDM4C IRF4 IGHV4-38-2 CD5
49 systemic lupus erythematosus 30.0 TNFAIP3 MYD88 MIR142 IRF4 CD79A CD5
50 lymphoma, non-hodgkin, familial 29.9 SPN MYD88 MME MIR142 MALT1 KDM4C

Graphical network of the top 20 diseases related to Marginal Zone B-Cell Lymphoma:



Diseases related to Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Marginal Zone B-Cell Lymphoma

GenomeRNAi Phenotypes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 BCL10 BIRC3 CARD11 CD40LG MYD88 TNFAIP3
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 BCL10 CARD11 MYD88 TNFAIP3

MGI Mouse Phenotypes related to Marginal Zone B-Cell Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.03 BCL10 BCL6 BIRC3 CARD11 CD19 CD40LG
2 hematopoietic system MP:0005397 10.03 BCL10 BCL6 BIRC3 CARD11 CCR6 CD19
3 immune system MP:0005387 9.86 BCL10 BCL6 BIRC3 CARD11 CCR6 CD19
4 integument MP:0010771 9.28 BCL6 CARD11 CD19 CD40LG CD5 KDM4C

Drugs & Therapeutics for Marginal Zone B-Cell Lymphoma

Drugs for Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 104)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
2
Chlorambucil Approved Phase 3 305-03-3 2708
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3
4
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
5
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
6
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
7
Ipilimumab Approved Phase 1, Phase 2 477202-00-9
8
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
9 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
10
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
11
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
12
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
13
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
14
rituximab Approved Phase 2 174722-31-7 10201696
15
Epirubicin Approved Phase 2 56420-45-2 41867
16
Obinutuzumab Approved, Investigational Phase 2 949142-50-1
17
Etoposide Approved Phase 2 33419-42-0 36462
18
Ifosfamide Approved Phase 2 3778-73-2 3690
19
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
20
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
21
Zanubrutinib Approved, Investigational Phase 2 1691249-45-2
22
Clarithromycin Approved Phase 2 81103-11-9 84029
23
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
24
Gemcitabine Approved Phase 2 95058-81-4 60750
25
ofatumumab Approved Phase 2 679818-59-8 6918251
26
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
27
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
28
Oprelvekin Approved, Investigational Phase 1, Phase 2 145941-26-0
29
Lenalidomide Approved Phase 2 191732-72-6 216326
30
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
31
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
32
Navitoclax Investigational Phase 1, Phase 2 923564-51-6
33 Veltuzumab Investigational Phase 1, Phase 2 728917-18-8
34 Bryostatin 1 Investigational Phase 2 83314-01-6
35
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
36 Complement System Proteins Phase 2
37 Gastrointestinal Agents Phase 2
38 Antiemetics Phase 2
39 Adjuvants, Immunologic Phase 2
40 Antimitotic Agents Phase 2
41 Tubulin Modulators Phase 2
42 Interleukin-12 Phase 2
43 Methylprednisolone Acetate Phase 2
44 Antineoplastic Agents, Immunological Phase 2
45 Antirheumatic Agents Phase 2
46 Pharmaceutical Solutions Phase 2
47 Alkylating Agents Phase 2
48 Etoposide phosphate Phase 2
49
Isophosphamide mustard Phase 2 100427
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 91)
# Name Status NCT ID Phase Drugs
1 Multicenter Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Completed NCT00210353 Phase 3 chlorambucil (drug);rituximab+chlorambucil;rituximab
2 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
3 A Phase III Multi-Center Randomized Controlled Trial of Low-Dose Radiotherapy for Follicular Lymphoma and Marginal Zone Lymphoma Completed NCT00310167 Phase 3
4 A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study of Ibrutinib in Combination With Rituximab in Subjects With Treatment Naïve Marginal Zone Lymphoma Recruiting NCT04212013 Phase 3 Ibrutinib;Rituximab
5 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma Not yet recruiting NCT04680052 Phase 3 tafasitamab;rituximab;lenalidomide;placebo
6 Phase II Study on Activity and Tolerability of Intralesional Rituximab in Patients With Relapsed or Refractory CD20+ Indolent Lymphomas of Conjunctiva; Activity of Supplemental Autologous Serum in Patients Not Responsive to Rituximab Alone Unknown status NCT01514344 Phase 2 intralesional rituximab
7 A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma Unknown status NCT01678404 Phase 2 131I-rituximab
8 A Prospective Single Arm Trial of Involved Field Radiotherapy Alone for Stage I-II Low Grade Non-gastric Marginal Zone Lymphoma Unknown status NCT00377195 Phase 2
9 Phase II Clinical Trial on the Activity of Salvage Therapy With High Dose Oral Clarithromycin in Patients With Relapsed or Refractory Extranodal Marginal Zone Lymphoma Unknown status NCT01516606 Phase 2 clarithromycin, oral, high dose
10 A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma Unknown status NCT03093831 Phase 2 Ibrutinib
11 A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies Completed NCT00406809 Phase 1, Phase 2 ABT-263
12 A Phase I Study of Immunotherapy With hA20 Administered Once Weekly for 4 Consecutive Weeks in Patients With CD20+ Non- Hodgkin's Lymphoma Completed NCT00596804 Phase 1, Phase 2 veltuzumab
13 A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
14 A Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus (RAD001) in Marginal Zone B-cell Lymphomas (MZL) EudraCT Number 2009-011725-14 Completed NCT01164267 Phase 2 Everolimus
15 A Phase II Study of Bryostatin 1 and Vincristine in Patients With Low or Intermediate Grade Non-Hodgkin's Lymphoma Progressing or Relapsing After a Prior Autologous Bone Marrow or Stem Cell Transplant Completed NCT00058305 Phase 2 bryostatin 1;vincristine sulfate
16 Randomized Phase II Study Of Interleukin-12 In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma Completed NCT00026182 Phase 2
17 A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease Completed NCT00003210 Phase 2
18 A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) Completed NCT02433795 Phase 2 bendamustine plus rituximab
19 A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas Completed NCT02254772 Phase 1, Phase 2 SD-101
20 R-CVP Followed by Rituximab Maintenance Therapy for Patients With Advanced Marginal Zone B-cell Lymphoma Completed NCT01213095 Phase 2 rituximab
21 Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142) Completed NCT00210327 Phase 2 Bortezomib (drug)
22 A Phase II Study of Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma Completed NCT01068392 Phase 2 Oxaliplatin, Prednisolone
23 Phase II Study of Ibritumomab Tiuxetan (Zevalin®) in Patients With Previously Untreated Marginal Zone Lymphoma Completed NCT00453102 Phase 2 Rituximab;Ibritumomab Tiuxetan
24 A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Completed NCT01980628 Phase 2 ibrutinib
25 A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma Completed NCT00253630 Phase 2 Vorinostat
26 A Phase 2 Clinical Trial of Rituximab, Cyclophosphamide, Bortezomib (VELCADE), and Dexamethasone (R-CYBOR-D) in Relapsed Low Grade and Mantle Cell Lymphoma Completed NCT00711828 Phase 2 Bortezomib;Cyclophosphamide;Dexamethasone
27 A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and R/R Indolent Lymphoma Completed NCT03520920 Phase 2 Zanubrutinib;Rituximab
28 Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (COUP-1) Recruiting NCT03474744 Phase 2 Copanlisib
29 MALIBU Trial - Phase II Study of Combination Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas Recruiting NCT03697512 Phase 2 Ibrutinib;Rituximab
30 A Single Arm, Multi-center, Phase II Clinical Trial of VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma Recruiting NCT04433156 Phase 2 Bortezomib;Rituximab;Epirubicin;Cyclophosphamide;Prednisone
31 Ublituximab as Initial Therapy for Treatment-naive Follicular or Marginal Zone Lymphoma With Response-driven Addition of Umbralisib for Suboptimal Response Recruiting NCT04508647 Phase 2 Ublituximab;Umbralisib
32 Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1) Recruiting NCT03322865 Phase 2 Obinutuzumab
33 A Multicenter, Open Label Single-Arm, Phase 2 Study of Zandelisib (ME-401) in Subjects With Follicular Lymphoma and Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies (The TIDAL Study) Recruiting NCT03768505 Phase 2 Zandelisib (ME-401)
34 A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Recruiting NCT03797456 Phase 2 ICP-022
35 A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma Recruiting NCT04298879 Phase 2 IBI376
36 A Phase 2 Study of Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma Recruiting NCT03919175 Phase 2 Umbralisib;Rituximab
37 A Phase 2, Open-Label Study of Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Non-Germinal Center Diffuse Large B Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Transformed Marginal Zone Lymphoma Recruiting NCT04189952 Phase 2 Acalabrutinib;Rituximab;Ifosfamide;Carboplatin;Etoposide
38 Radiation Therapy Alone for Stage 1 and 2 MALT (Mucosa-Associated Lymphoid Tissue) Lymphoma Active, not recruiting NCT04465162 Phase 2
39 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study Active, not recruiting NCT02853370 Phase 2 Bendamustine and Rituximab
40 A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma) Active, not recruiting NCT01808599 Phase 2 Chlorambucil;Rituximab i.v.;Rituximab s.c.
41 International Prospective Phase 2 Trial Addressing the Efficacy of First-line Chlamydophila Psittaci-eradicating Therapy With Protracted Administration of Doxycycline Followed by Eradication Monitoring and Antibiotic Re-treatment at Infection Re-occurrence in Patients With Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL) Active, not recruiting NCT01820910 Phase 2 Doxycycline
42 A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma Active, not recruiting NCT03846427 Phase 2 Zanubrutinib
43 An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma Active, not recruiting NCT02532257 Phase 2 Ibrutinib;Lenalidomide
44 A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204) Active, not recruiting NCT03144674 Phase 2 Parsaclisib
45 A Phase II Trial Addressing Feasibility and Activity of Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma Active, not recruiting NCT03031483 Phase 2 clarithromycin and lenalidomide
46 A Phase II Trial of Combination of Oral Lenalidomide and Low-dose Cyclophosphamide for Patients With Antibiotics-unresponsive Extranodal Marginal Zone B-cell Lymphoma Not yet recruiting NCT04604028 Phase 2 Lenalidomide [Leavdo®]
47 Phase II Trial of Acalabrutinib in Combination With Tafasitamab in Patients With Previously Treated Marginal Zone Lymphomas (MZL) Not yet recruiting NCT04646395 Phase 2 Tafasitamab;Acalabrutinib
48 A Multi-center, Open Label, Phase 1b/2 Study to Study the Efficacy and Safety of MIL62 Plus Lenalidomide in Subjects With Relapsed/Refractory Follicular Lymphoma or Marginal Zone Lymphoma Not yet recruiting NCT04110301 Phase 1, Phase 2 Recombinant Humanized Monoclonal Antibody MIL62 Injection;Lenalidomide
49 A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma Not yet recruiting NCT04416451 Phase 2 Rituximab;Venetoclax
50 Phase II Study of Gemcitabine in Patients With Advanced Stage Marginal Zone B-cell Lymphoma Terminated NCT00337259 Phase 2 gemcitabine

Search NIH Clinical Center for Marginal Zone B-Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Marginal Zone B-Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Marginal Zone B-Cell Lymphoma

Anatomical Context for Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Marginal Zone B-Cell Lymphoma:

40
Bone Marrow, Breast, Thyroid, B Cells, Skin, Spleen, Myeloid

Publications for Marginal Zone B-Cell Lymphoma

Articles related to Marginal Zone B-Cell Lymphoma:

(show top 50) (show all 2833)
# Title Authors PMID Year
1
Masson Trichrome and Sulfated Alcian Blue Stains Distinguish Light Chain Deposition Disease From Amyloidosis in the Lung. 61
33002919 2021
2
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma. 61
33560394 2021
3
Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. 61
33145711 2021
4
A deep molecular response of splenic marginal zone lymphoma to front-line checkpoint blockade. 61
33054119 2021
5
Development and validation of a prognostic nomogram for gastric marginal zone lymphoma: a Surveillance, Epidemiology and End Results-based population study. 61
33401980 2021
6
A Case Report of Small Lymphocytic Lymphoma Mimicking Primary Cutaneous Marginal Zone Lymphoma With Plasmacytic Differentiation. 61
33606375 2021
7
Improved primary staging of marginal zone lymphoma by addition of CXCR4-directed PET/CT. 61
33579803 2021
8
Long-term Therapeutic Success of Intravenous Rituximab in 26 Patients with Indolent Primary Cutaneous B-cell Lymphoma. 61
33475146 2021
9
Peripheral blood morphology review and diagnostic proficiency evaluation by a new Spanish EQAS during the period 2011-2019. 61
32870604 2021
10
Primary IgG4-producing extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in the cavernous sinus: A mimicker of IgG4-related disease/hypertrophic pachymeningitis. 61
33524189 2021
11
4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. 61
33539729 2021
12
Primary marginal zone B-cell lymphoma of the cavernous sinus: a case report and review of the literature. 61
33579209 2021
13
Genome-wide DNA methylation analysis along the progression of gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type. 61
33590882 2021
14
Tertiary lymphoid structures with overlapping histopathologic features of cutaneous marginal zone lymphoma during neoadjuvant cemiplimab therapy are associated with antitumor response. 61
33399228 2021
15
Mutational Analysis Reinforces the Diagnosis of Nodal Marginal Zone Lymphoma With Robust PD1-positive T-Cell Hyperplasia. 61
32520760 2021
16
Regression of Marginal Zone Lymphoma After Praziquantel Therapy in a Patient With Remote Schistosoma haematobium Infection. 61
33509726 2021
17
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue. 61
33496731 2021
18
Whole brain radiation therapy for primary central nervous system marginal zone lymphoma: a case report. 61
33489698 2021
19
Survival of patients with marginal zone lymphoma in the United States: A population-based cohort study (2000 to 2017). 61
33476433 2021
20
MALT Lymphoma of the Urinary Bladder Shows a Dramatic Female Predominance, Uneven Geographic Distribution, and Possible Infectious Etiology. 61
33575225 2021
21
Epidemiology of Non-Hodgkin's Lymphoma. 61
33573146 2021
22
Primary Pulmonary B-Cell Lymphoma: A Review and Update. 61
33499258 2021
23
Follicular colonization in chronic lymphocytic leukemia/small lymphocytic lymphoma (comment on "Small lymphocytic lymphoma mimicking primary cutaneous marginal zone lymphoma with colonization of germinal center follicles"). 61
33410535 2021
24
Primary cutaneous lymphomas in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): A series of 12 cases. 61
33415780 2021
25
Notch activation is pervasive in SMZL and uncommon in DLBCL: implications for Notch signaling in B-cell tumors. 61
33570635 2021
26
Small lymphocytic lymphoma mimicking primary cutaneous marginal zone lymphoma with colonization of germinal center follicles. 61
32506455 2021
27
Imaging of head and neck mucosa-associated lymphoid tissue lymphoma (MALToma). 61
33436095 2021
28
Lack of clinical relevance of blood clonality in primary cutaneous marginal zone B-cell lymphoma. 61
33495148 2021
29
Cutaneous Lymphomas -Part II: Other Cutaneous Lymphomas. 61
33045210 2021
30
Two Cases of Crystal-storing Histiocytosis Diagnosed by Morphology, Immunohistochemistry, and Ultrastructural Examination. 61
31135447 2021
31
Diffuse Small B-Cell Lymphoma: A High-Grade Malignancy. 61
33461440 2021
32
Recent advances upper gastrointestinal lymphomas: molecular updates and diagnostic implications. 61
33382495 2021
33
The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study. 61
33455071 2021
34
Radiologically-guided percutaneous core needle biopsy of the spleen: a reliable and safe diagnostic procedure for neoplastic and reactive conditions. 61
33393079 2021
35
Long-term outcomes of frontline 90Y-ibritumomab tiuxetan in marginal zone lymphoma. 61
32755329 2020
36
Darier sign in a teenager with primary cutaneous marginal zone lymphoma. 61
33336458 2020
37
Distribution of CD1a-positive cells is not different between pseudolymphomatous folliculitis and primary cutaneous marginal zone lymphoma. 61
33326629 2020
38
Extranodal B-cell marginal zone lymphoma arising in the context of a lympho-epithelial cyst of the parotid gland in a patient with clonal B-cell lymphocytosis: report of the first case. 61
33325453 2020
39
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. 61
32650677 2020
40
Diagnostic challenges in an aggressive case of peripheralizing marginal zone lymphoma. 61
33363923 2020
41
Treatment outcomes of IgG4-producing marginal zone B-cell lymphoma: a retrospective case series. 61
32785819 2020
42
Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities. 61
33314017 2020
43
RNA sequencing analyses reveal differentially expressed genes and pathways as Notch2 targets in B-cell lymphoma. 61
33400727 2020
44
Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma. 61
33283568 2020
45
Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey. 61
33303706 2020
46
Tracking the Genetic Susceptibility Background of B-Cell Non-Hodgkin's Lymphomas from Genome-Wide Association Studies. 61
33374413 2020
47
The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib. 61
33428844 2020
48
Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice. 61
33311649 2020
49
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. 61
33353234 2020
50
Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. 61
32249238 2020

Variations for Marginal Zone B-Cell Lymphoma

Expression for Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Marginal Zone B-Cell Lymphoma.

Pathways for Marginal Zone B-Cell Lymphoma

Pathways related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.72 TNFAIP3 SIGLEC5 MYD88 MME MALT1 IRF4
2
Show member pathways
13.32 SIGLEC5 MYD88 MALT1 CD79A CD40LG CD19
3
Show member pathways
12.6 MALT1 CD79A CD19 CARD11 BCL10
4
Show member pathways
12.55 TNFAIP3 MYD88 MALT1 CD40LG CARD11 BCL10
5
Show member pathways
12.5 MALT1 CD79A CD40LG CARD11 BCL10
6
Show member pathways
12.39 MYD88 MALT1 IRF4 CD40LG CARD11 BCL10
7
Show member pathways
12.32 MALT1 CD19 CARD11 BCL6 BCL10
8
Show member pathways
12.27 MALT1 CD40LG CARD11 BCL10
9
Show member pathways
12.09 MALT1 IRF4 CD79A CD19 CARD11 BCL6
10 12.07 TNFAIP3 MALT1 CD40LG BIRC3 BCL10
11 11.84 TNFAIP3 MYD88 MALT1 IRF4 CD79A CD40LG
12
Show member pathways
11.81 MALT1 CARD11 BCL10
13 11.78 SPN MME CD79A CD5 CD19
14 11.76 MME CD5 CD19
15 11.6 SPN MME IRF4 CD19
16 11.57 CD40LG CCR6 BCL6
17 11.53 IRF4 CD40LG BCL6
18 11.52 TNFAIP3 MYD88 MALT1 CD40LG CARD11 BIRC3
19 11.28 CD79A CD40LG CD19
20 11.16 TNFAIP3 CD40LG BIRC3
21 11.01 TNFAIP3 MALT1 BCL10

GO Terms for Marginal Zone B-Cell Lymphoma

Cellular components related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.63 MME CD79A CD19 CARD11 BIRC3 BCL10
2 external side of plasma membrane GO:0009897 9.5 SPN IGHV4-38-2 CD79A CD5 CD40LG CD19
3 polkadots GO:0002096 9.26 MALT1 BCL10
4 CBM complex GO:0032449 8.8 MALT1 CARD11 BCL10

Biological processes related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10 MYD88 MALT1 CD40LG BIRC3 BCL6
2 immune system process GO:0002376 9.98 MYD88 IRF4 CD79A CD19 C1S BCL6
3 regulation of apoptotic process GO:0042981 9.85 MALT1 CARD11 BIRC3 BCL6 BCL10
4 cellular response to lipopolysaccharide GO:0071222 9.84 TNFAIP3 MYD88 MALT1 BCL10
5 regulation of inflammatory response GO:0050727 9.79 MYD88 BIRC3 BCL6
6 positive regulation of protein ubiquitination GO:0031398 9.77 MALT1 BIRC3 BCL10
7 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.77 CARD11 BIRC3 BCL10
8 T cell costimulation GO:0031295 9.73 CD5 CD40LG CARD11
9 cellular defense response GO:0006968 9.72 SPN CCR6 BCL10
10 regulation of immune response GO:0050776 9.72 SPN CD40LG CD19 CARD11 BCL6
11 B cell proliferation GO:0042100 9.69 CD79A CD40LG CARD11
12 lipopolysaccharide-mediated signaling pathway GO:0031663 9.67 MYD88 MALT1 BCL10
13 positive regulation of interleukin-2 production GO:0032743 9.65 MALT1 IRF4 CARD11
14 regulation of T cell migration GO:2000404 9.58 SPN CCR6
15 regulation of T cell receptor signaling pathway GO:0050856 9.58 MALT1 BCL10
16 response to fungus GO:0009620 9.57 MALT1 BCL10
17 B cell differentiation GO:0030183 9.56 CD79A CD40LG CARD11 BCL6
18 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.55 MYD88 MALT1 CARD11 BIRC3 BCL10
19 positive regulation of T cell activation GO:0050870 9.54 MALT1 CARD11 BCL10
20 regulation of germinal center formation GO:0002634 9.52 TNFAIP3 BCL6
21 B-1 B cell differentiation GO:0001923 9.4 MALT1 CD19
22 immunoglobulin mediated immune response GO:0016064 9.13 MYD88 CD19 BCL10
23 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.02 MYD88 MALT1 CD40LG CARD11 BCL10

Molecular functions related to Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.33 TNFAIP3 MALT1 BCL10
2 CARD domain binding GO:0050700 9.26 CARD11 BCL10
3 kinase activator activity GO:0019209 8.96 MALT1 BCL10
4 protein self-association GO:0043621 8.92 TNFAIP3 MYD88 MALT1 BCL10

Sources for Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....